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Hospital treatment, mortality and healthcare
costs in relation to socioeconomic status among
people with bipolar affective disorder
Yi-Ju Pan, Ling-Ling Yeh, Yu-Chun Chen, Kuei-Hong Kuo and Chin-Kuo Chang
Background
Evidence regarding the relationships between the
socioeconomic status and long-term outcomes of individuals
with bipolar affective disorder (BPD) is lacking.
Aims
We aimed to estimate the effects of baseline socioeconomic
status on longitudinal outcomes.
Method
A national cohort of adult participants with newly diagnosed BPD
was identified in 2008. The effects of personal and household
socioeconomic status were explored on outcomes of hospital
treatment, mortality and healthcare costs, over a 3-year follow-up
period (2008–2011).
Results
A total of 7987 participants were recruited. The relative risks of
hospital treatment and mortality were found elevated for the
ones from low-income households who also had higher
healthcare costs. Low premium levels did not correlate with
future healthcare costs.
Conclusions
Socioeconomic deprivation is associated with poorer outcome
and higher healthcare costs in BPD patients. Special care
should be given to those with lower socioeconomic status to
improve outcomes with potential benefits of cost savings in the
following years.
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Compared with research about the associations between socio-
economic status and risk for bipolar affective disorder (BPD),1,2
fewer studies have examined the relationships between baseline
socioeconomic status and long-term outcomes for individuals
living with BPD. Although several studies suggested higher
socioeconomic status may be related to better symptomatic or
functional consequnces,3–5 other studies failed to detect significant
influences of socioeconomic status on readmissions, global
assessment of functioning and time with depressive/manic symp-
toms in longitudinal follow-ups.6,7 In comparison with the general
population, the mortality rate is substantially higher for indi‐
viduals with BPD, considered as one of the serious mental
illnesses,8,9 and this mortality gap may be getting wider in recent
years.10 Given the well-recognised differences in mortality across
socioeconomic groups,11 data exploring the impacts of socio-
economic deprivation on excess mortality in people with BPD
remain wanting.
Regarding the existing evidence, there are some flaws. First,
earlier studies on socioeconomic status and treatment outcomes
only recruited hospitalised individuals from a single centre.3,6 The
generalisability is questionable because socioeconomic status may
vary considerably across catchment areas. Second, nearly all of the
previous studies were from the USA,3,4,6,7 where financial barriers
to healthcare services were extremely high to the most disadvan-
taged people.12 Third, the applied socioeconomic status measure-
ments mainly focused on the affected person’s education level and
recent occupations which could be the consequences of illness
resulting from early social decline.13 Lastly, very few studies
explored the socioeconomic status effects on outcome of excess
mortality in the populations with serious mental illnesses.14 None
of them specifically examined the relationships between socio-
economic deprivation and all-cause mortality in people with BPD.
Therefore, the current exploratory study, using the claims data
from the National Health Insurance Research Database (NHIRD)
in Taiwan, sought to explore the impacts of baseline socio-
economic status at both personal and household levels on
longitudinal outcomes of hospital treatment and mortality in a
nationally representative sample of people with newly diagnosed
BPD. Considering the need to understand factors affecting
healthcare costs and to alleviate healthcare cost burden, the
associations between socioeconomic status measurements and
healthcare costs were also explored in a follow-up period of
consecutive 3 years, from the perspectives of healthcare providers.
Method
Setting
Taiwan is a country with a population of around 23 million. On a
purchasing power parity basis, its gross domestic product per capita
in 2008/2009 was 31 100/32 000 international dollars. National
Health Insurance (NHI) in Taiwan is a single-payer compulsory
social insurance system which centralises the disbursement of
healthcare funds and guarantees equal access to healthcare for all
citizens. In 2008, a total of 22.92 million individuals were involved
in Taiwan’s NHI programme with a coverage rate of 99.48%.15
The NHIRD consists of data characterising healthcare utilisation
of insured residents, including expenditures, medical procedures/
treatments and basic demographic characteristics. Diagnosis in
NHIRD is given with the International Classification of Diseases,
9th revision, clinical modification diagnoses (ICD-9-CM). In this
study, all participants were first identified from the NHIRD, and the
index date was defined as the date on which the participant was first
diagnosed with BPD (ICD-9-CM codes: 296.0, 296.1, 296.4–296.7) in
2008. Data on all NHI information for each participant were extracted
for the 1 year preceding, and 3 years following the index date.
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The study protocol was approved by the Research Ethics Review
Committee of Far EasternMemorial Hospital, Taiwan (No. 102006-F).
Participants
All participants meeting the following criteria in NHIRD were
included in the study.
. They were diagnosed with BPD in 2008.
. They were aged 18 years or above on the index date.
. Data were available for a minimum of 12 months before
and 36 months after the index date.
. They did not have a diagnosis of BPD in the year
preceding the index date.
To ensure the validity of the clinical diagnoses, participants
needed to have at least four out-patient visits because of treatment
of BPD or one hospital treatment with BPD as the primary
diagnosis in the year following the index date.
Service use and costs
The extracted service use components included out-patient
services, emergency attendances and in-patient stays. Service use
during the preceding year and over the consecutive 3-year study
period following the index date was extracted. All costs were
calculated from the actual claims data, and expressed in 2008–
2009 New Taiwan Dollar (NTD; the implied purchasing power
parity conversion rate between 2008–2009 NTD and International
Dollar is 16.99:1).16
Demographic/clinical information and baseline
socioeconomic status measurements
Demographic and clinical data were extracted, including age,
gender, physician specialty clinical setting and type of mood
episode on the index date. The baseline socioeconomic status
variables included low-income household as recognised by the
government (those whose total income divided by the number of
household members is lower than the minimum cost of living,
which is set at 60% of the average monthly per capita non-
productive expenditure during the past year), insurance premium
level (the monthly salary-based income of the insured, which is
categorised into four levels: above NTD 72 801, NTD 36 301–
72 800, NTD 17 281–36 300, below NTD 17 280 (International
Dollar 1=NTD 16.99)),16 and urbanisation level of residence
(urbanisation stratifications of townships in Taiwan according
to population density, population ratio of people with college or
above educational levels, population ratio of people of agricultural
employment population ratio of elderly people and physician
density)17 on the index date. For all participants, comorbidities
of mental and physical illnesses, as well as healthcare utilisation/
expenditure, were traced back for the 12 months prior to the
index date.
Healthcare utilisation pattern within the first year of
index diagnosis
Healthcare utilisation pattern was operationally defined by
whether the individual had been admitted for treatment of BPD
as well as the frequency of out-patient visits for BPD treatment
within the first year of diagnosis. Because the individual who had
been admitted for treatment of BPD may differ considerably from
those receiving treatments exclusively at out-patient settings, we
categorised study participants into three mutually exclusive groups
based on the healthcare utilisation pattern for BPD treatment
within the first year: (1) those who were admitted for treatment of
BPD; (2) those having ≥7 out-patient clinic visits; and (3) those
having four to six out-patient clinic visits.
Data analysis
Basic demographic/clinical data, socioeconomic status measurements
and healthcare expenditure for the preceding year were described
for the overall sample and compared among groups according to
their first-year healthcare utilisation patterns. Survival analyses with
Kaplan–Meier curves and Cox regressions were employed to estimate
the effects of baseline socioeconomic status factors on the risks
of being hospitalised within the consecutive 3 years. The considered
confounding factors included demographic/clinical information and
comorbid physical/mental illnesses within the preceding year.
To further identify characteristics predictive of healthcare
costs over the second and third years respectively generalised
linear regression models with a log link and gamma variance
function and baseline socioeconomic status variables as major
predictors of interest were employed.18 The generalised linear
model allows a generalisation of the response distribution to
members of the exponential family, including gamma, inverse
Gaussian and binomial distributions. Given the assumption for a
constant coefficient of variation, the gamma distribution has been
found to be appropriate for cost analyses. In a generalised linear
model, the regression equation is called the ‘linear predictor’ but
this linear predictor is not equated with the expected cost, but via
‘link function’. The log link is commonly used when analysing
cost data because it guarantees non-negative outcomes and has a
close connection to the logarithmic transformation of data. This
generalised linear model approach has been commonly used in
analyses of economic cost data.19
Standardised mortality ratios (SMRs) were calculated for the
3-year observation period. Death was defined as withdrawal of the
person from the NHI programme.20 SMRs were calculated using
age (namely 18–19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49,
50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85–89 and 90+)
and gender strata.21 The number of deaths observed in these 3 years
represented the numerator. The denominator was the expected
number of deaths in a year estimated by age- and gender-specific
mortality statistics for the Taiwanese population in 2009/2010
multiplied by three. To assure for the validity of this proxy
definition of death status, a set of sensitivity analysis for SMRs
was calculated with another target population consisting of people
who had no diagnoses of mental illnesses during medical encounters
in 2008, retrieved from a random sample of 200 000 beneficiaries
from the Longitudinal Health Insurance Database 2005, which
provided a population representative cohort including nearly one
million of the year 2005 Registry of Beneficiaries (22.17 million)
under Taiwan’s NHI programme. All statistical analyses were
performed via SPSS version 17.0 (Chicago, Illinois, USA). Alpha
level was set at 0.05 (P-value) for statistical significance.
Results
Initially, there were 15 254 adult participants with newly diagnosed
BPD. Among them, 7267 were subsequently excluded because they
did not have at least four out-patient visits because of treatment of
BPD or one hospital treatment with BPD as the primary diagnosis
in the year following the index date. There are totally 7987 participants
with newly diagnosed BPD included in the current analyses.
On the index date, the mean age was 44.3 (s.d.=16.2), around
40.8% male and 3.3% classified as from low-income households.
The income premium distributions from the lowest to the highest
level were 58.5%, 33.6%, 7.1% and 0.8% respectively. At first
diagnosis, the affective presentations were manic (47.1%), mixed
(13.6%), depressed (26.5%) and unspecified (12.8%). Within the
first year, 29.2% of the participants were admitted at least once for
BPD treatments (Table 1).
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Table 1 Sociodemographic and clinical characteristics, stratified by healthcare utilisation patterna within the first year of index diagnosis
Characteristics
Hospital
treatment
(n=2329)
OPD ≥7
(n=3823)
OPD 4–6
(n=1835)
Total
(n=7987) Significance
Age [mean (s.d.)] 43.84 (16.23) 44.05 (15.78) 45.48 (16.97) 44.32 (16.20) F=6.252, P=0.002*
Gender [n (%)] χ2=59.600, P<0.001**
Male 1104 (47.4) 1442 (37.7) 715 (39.0) 3261 (40.8)
Female 1225 (52.6) 2381 (62.3) 1120 (61.0) 4726 (59.2)
Low-income household [n (%)] 98 (4.2) 117 (3.1) 49 (2.7) 264 (3.3) χ2=8.968, P=0.011*
Insurance premiumb [n (%)] χ2=59.702, P<0.001**
Level (1) 1487 (63.8) 2155 (56.4) 1033 (56.3) 4675 (58.5)
Level (2) 725 (31.1) 1325 (34.7) 631 (34.4) 2681 (33.6)
Level (3) 110 (4.7) 310 (8.1) 149 (8.1) 569 (7.1)
Level (4) 7 (0.3) 33 (0.9) 22 (1.2) 62 (0.8)
Urbanisation levelc [n (%)] χ2=42.778, P<0.001**
Level (1) 669 (28.7) 1183 (30.9) 631 (34.4) 2483 (31.1)
Level (2) 648 (27.8) 1191 (31.2) 527 (28.7) 2366 (29.6)
Level (3) 332 (14.3) 541 (14.2) 264 (14.4) 1137 (14.2)
Level (4) 358 (15.4) 489 (12.8) 212 (11.6) 1059 (13.3)
Level (5) 37 (1.6) 44 (1.2) 28 (1.5) 109 (1.4)
Level (6) 84 (3.6) 105 (2.7) 54 (2.9) 243 (3.0)
Level (7) 201 (8.6) 270 (7.1) 119 (6.5) 590 (7.4)
Clinical setting at index visit [n (%)] χ2=4487.668, P<0.001**
OPD 721 (31.0) 3743 (97.9) 1777 (96.8) 6241 (78.1)
ER 227 (9.7) 80 (2.1) 58 (3.2) 365 (4.6)
In-patient 1381 (59.3) 0 (0.0) 0 (0.0) 1381 (17.3)
Physician type at index visit [n (%)] χ2=113.512, P<0.001**
Non-psychiatrist 599 (25.7) 683 (17.9) 545 (29.7) 1827 (22.9)
Psychiatrist 1730 (74.3) 3140 (82.1) 1290 (70.3) 6160 (77.1)
Catastrophic illness cardd [n (%)] 863 (37.1) 883 (23.1) 323 (17.6) 2069 (25.9) χ2=232.449, P<0.001**
Initial diagnosis codese [n (%)] χ2=716.779, P<0.001**
296.0 308 (13.2) 635 (16.6) 435 (23.7) 1378 (17.3)
296.1 228 (9.8) 220 (5.8) 132 (7.2) 580 (7.3)
296.4 813 (34.9) 693 (18.1) 292 (15.9) 1798 (22.5)
296.5 316 (13.6) 1245 (32.6) 559 (30.5) 2120 (26.5)
296.6 208 (8.9) 627 (16.4) 253 (13.8) 1088 (13.6)
296.7 456 (19.6) 403 (10.5) 164 (8.9) 1023 (12.8)
Total healthcare costs in the preceding year
(in 1000 NTD)
[mean (s.d.)]
77 (133) 56 (100) 51 (99) 61 (111) F=34.863, P<0.001**
Comorbid physical illnessf [n (%)]
Hypertension 454 (19.5) 736 (19.3) 387 (21.1) 1577 (19.7) χ2=2.774, P=0.250
Diabetes mellitus 248 (10.6) 408 (10.7) 181 (9.9) 837 (10.5) χ2=0.964, P=0.618
Renal disease 100 (4.3) 138 (3.6) 81 (4.4) 319 (4.0) χ2=2.863, P=0.239
Cancer 84 (3.6) 118 (3.1) 67 (3.7) 269 (3.4) χ2=1.790, P=0.409
Cardiovascular disease 406 (17.4) 692 (18.1) 411 (22.4) 1509 (18.9) χ2=19.517, P<0.001**
Chronic obstructive pulmonary disease 273 (11.7) 424 (11.1) 209 (11.4) 906 (11.3) χ2=0.578, P=0.749
Stroke 76 (3.3) 123 (3.2) 74 (4.0) 273 (3.4) χ2=2.736, P=0.255
Parkinson’s disease 51 (2.2) 75 (2.0) 48 (2.6) 174 (2.2) χ2=2.490, P=0.288
Comorbid painful physical symptomf
[n (%)]
Headache/migraine/dizziness 699 (30.0) 1382 (36.1) 692 (37.7) 2773 (34.7) χ2=33.459, P<0.001**
Back pain 525 (22.5) 1060 (27.7) 522 (28.4) 2107 (26.4) χ2=25.273, P<0.001**
Comorbid mental illnessf [n (%)]
Major depression 556 (23.9) 1360 (35.6) 474 (25.8) 2390 (29.9) χ2=113.530, P<0.001**
Other depression 598 (25.7) 1238 (32.4) 502 (27.4) 2338 (29.3) χ2=35.666, P<0.001**
Schizophrenia 421 (18.1) 353 (9.2) 103 (5.6) 877 (11.0) χ2=185.993, P<0.001**
Other psychotic disorder 228 (9.8) 199 (5.2) 76 (4.1) 503 (6.3) χ2=70.309, P<0.001**
Substance use disorder 187 (8.0) 215 (5.6) 90 (4.9) 492 (6.2) χ2=20.981, P<0.001**
Alcohol use disorders 77 (3.3) 37 (1.0) 19 (1.0) 133 (1.7) χ2=54.097, P<0.001**
Hyperkinetic syndrome 3 (0.1) 14 (0.4) 10 (0.5) 27 (0.3) χ2=5.448, P=0.066
Panic disorder 49 (2.1) 207 (5.4) 69 (3.8) 325 (4.1) χ2=41.221, P<0.001**
Deaths in first year of follow-up [n (%)] 92 (4.0) 47 (1.2) 47 (2.6) 186 (2.3) χ2=47.670, P<0.001**
Deaths in second year of follow-up [n (%)] 151 (6.5) 107 (2.8) 78 (4.3) 336 (4.2) χ2=48.770, P<0.001**
Deaths in third year of follow-up [n (%)] 215 (9.2) 164 (4.3) 118 (6.4) 497 (6.2) χ2=60.742, P<0.001**
Pan et al
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Baseline socioeconomic status in relation to hospital
treatment outcome
The Kaplan–Meier curves showed that individuals from low-
income households had remarkably worse survival curves in terms
of hospital treatment compared with the others with a log-rank
test of P<0.01 in each of 1-, 2- and 3-year follow-ups. Individuals
with lower premium levels also significantly differed in survival
curves regarding hospital treatment compared with those with
higher premium levels (Fig. 1). The results of Cox regression
revealed that the group of low-income household had an over 40%
increase in the risk of hospital treatment in each of the 1-year, 2-
year and 3-year follow-ups. Compared with the group with the
highest insurance premium, the lower premium levels predicted
hospital treatment in the 2-year and 3-year follow-ups. Urbanisa-
tion level was not significantly associated with hospital treatment.
Apart from the socioeconomic status factors, younger age and
male gender were shown to be associated with higher rates of
being hospitalised (Table 2).
Baseline socioeconomic status in relation to future
total healthcare costs
As revealed in Table 3, low-income household predicted higher
healthcare costs in the second and third years respectively,
whereas the individual’s baseline premium levels did not sig-
nificantly correlate with future healthcare costs. Urbanisation
levels also correlated with future total healthcare costs in the
second and third years. With regard to other factors, older age and
male gender were shown to be associated with higher total
healthcare costs in the second and third years (Table 3).
Baseline socioeconomic status in relation to mortality
outcome
In this group of newly diagnosed BPD, a nearly threefold increase of
relative risk ofmortality was identified (SMR=2.97, 95%CI=2.71, 3.24)
with age- and gender-standardisation. Men with newly diagnosed
BPD had an SMR of 3.42 (95% CI=3.04, 3.82), whereas their female
counterparts had an SMR of 2.45 (95% CI=2.12, 2.83). A sensitivity
analysis for the control group of people without mental illness
diagnoses yielded an SMR of 1.08 (95% CI=1.04, 1.12). With regard
to baseline socioeconomic status factors, BPD individuals with the
lowest premium level had an SMR of 3.00 (95% CI=2.68, 3.33). For
participants whose premium levels were NTD 17 281–36 300, 36 301–
72 800 and ≥72 801, the SMRs were 3.01 (95% CI=2.54, 3.54), 2.29
(95% CI=1.28, 3.77) and 2.07 (95% CI=0.25, 7.48) respectively.
More notably, the mortality risk of bipolar disorder participants from
low-income households was over five times higher than the general
Table 1 (Continued)
Characteristics
Hospital
treatment
(n=2329)
OPD ≥7
(n=3823)
OPD 4–6
(n=1835)
Total
(n=7987) Significance
Hospital treatment in first year of follow-upg
[n (%)]
1883 (80.9) 205 (5.4) 106 (5.8) 2194 (27.5) χ2=4775.633, P<0.001**
Hospital treatment in second year of
follow-upg [n (%)]
1907 (81.9) 382 (10.0) 157 (8.6) 2446 (30.6) χ2=4161.064, P<0.001**
Hospital treatment in third year of
follow-upg [n (%)]
1917 (82.3) 477 (12.5) 188 (10.2) 2582 (32.3) χ2=3841.458, P<0.001**
s.d., Standard deviation; OPD, out-patient department; ER, emergency room.
a. Study participants were grouped by first-year healthcare utilisation pattern for treatment of BPD: hospital treatment, participants who had been admitted at least once during the first
year; OPD ≥7, participants who had not been admitted and had ≥7 out-patient visits during the first year; OPD 4–6, participants who had not been admitted and had 4–6
out-patient visits during the first year.
b. Insurance premium was classified into four different levels: Level (1): Under 17 280 NTD; Level (2): Between 17 281 NTD and 36 300 NTD; Level (3): Between 36 301 NTD and 72 800
NTD; Level (4): Above 72 801 NTD.
c. Urbanisation was classified into seven different levels: Level (1): Metropolitan city; Level (2): City; Level (3): Developing city; Level (4): Town; Level (5): Ageing population town; Level (6):
Agricultural town; Level (7): Rural area.
d. If a patient is diagnosed with a catastrophic illness by a physician under Ministry of Health and Welfare guidelines, the patient can apply for a catastrophic illness card with which the
patient does not need to pay a copayment for out-patient or in-patient care for related conditions.
e. 296.0, 296.1, 296.4 represents manic states; 296.5 represents depressive states; 296.6 represents mixed states; and 296.7 represents unspecified mood states.
f. Comorbid physical and mental illnesses were measured over the 12-month pre-index period. Costs were expressed in New Taiwan Dollar (NTD). Chi-squared test was used for
comparing categorical variables between groups by first-year healthcare utilisation pattern and ANOVA was used for comparisons of continuous variables.
g. Hospital treatment during which the patients were first diagnosed on the index dates were not included.
*P<0.05, **P<0.001.
Fig. 1. Socioeconomic status groups and time to the ﬁrst hospital treatment.
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population (SMR for low-income males=5.51, 95% CI=3.21, 8.81;
SMR for low-income females=6.47, 95% CI=2.96, 12.28; Table 4).
Discussion
Based on a nationally representative sample of participants with
newly diagnosed BPD, the current study has provided evidence of
the negative impacts of socioeconomic deprivation on longitudinal
outcomes of hospital treatment and mortality. It also provided the
rarely available data concerning the associations between baseline
socioeconomic status measurements and total healthcare costs
over the consecutive 3 years. This is the first study specifically
addressing the effects of baseline socioeconomic status measure-
ments at both personal and household levels on outcomes of
hospital treatment, excess mortality and total healthcare costs of
participants with newly diagnosed BPD.
The current results indicated the presence of differential
associations between BPD patients’ hospital treatment, healthcare
costs and baseline socioeconomic status measurements at personal
and household levels. Briefly, the individual’s baseline premium
level (as a proxy for personal socioeconomic status) predicted
hospital treatment but not total healthcare costs in the following
years. Contrarily, low-income household (as a proxy for family
socioeconomic status) predicted both hospital treatment and total
healthcare costs in the following years. In keeping with past
studies showing that BPD participant’s premorbid functioning
best predicts future outcome,4 our results suggested that the
higher baseline premium levels, roughly correlated with better
premorbid occupational functioning of the affected individuals,
the lower the likelihoods of being hospitalised in the second and
third years after the index date. However, only household income
(but not the affected individual’s baseline premium level)
predicted the individual’s total healthcare costs, implying that
the family level index may be the better socioeconomic status
measurement in this context, which reflects the collective financial
and social resources available to the affected individual to
consume. From the perspective of healthcare providers, indivi-
duals from low-income households may place a greater burden on
medical resources probably because of lack of alternative
resources, which underlines the need to address inequalities and
the importance of resources reallocation. If other family and social
costs are taken into consideration, whether bipolar disorder
individuals across socioeconomic groups differ in the costs to
the society remains to be determined.
The higher rates of hospital treatment and the over five times
higher SMR in bipolar disorder individuals from low-income
households correspond with the poverty-related barriers to health-
care.22 Although unaffordable insurance premiums or copayments
Table 2 Factors predicting hospital treatment in 1-year, 2-year and 3-year follow-up
1-year follow-up 2-year follow-up 3-year follow-up
Exp(β) 95% CI Exp(β) 95% CI Exp(β) 95% CI
Age 0.993 (0.990, 0.997)** 0.993 (0.990, 0.996)** 0.993 (0.989, 0.996)**
Gender
Male v. female 1.115 (1.021, 1.218)* 1.129 (1.038, 1.227)* 1.141 (1.052, 1.238)*
Low-income household
Yes v. no 1.429 (1.152, 1.771)* 1.430 (1.163, 1.758)* 1.461 (1.196, 1.785)**
Insurance premiuma
Level (1) v. Level (4) 2.100 (0.870, 5.069) 2.572 (1.066, 6.205)* 2.837 (1.176, 6.842)*
Level (2) v. Level (4) 1.871 (0.774, 4.522) 2.264 (0.937, 5.466) 2.473 (1.024, 5.969)*
Level (3) v. Level (4) 1.723 (0.701, 4.233) 2.147 (0.877, 5.257) 2.366 (0.967, 5.786)
Urbanisation levelb
Level (1) v. Level (7) 0.951 (0.804, 1.123) 0.953 (0.813, 1.118) 0.948 (0.812, 1.108)
Level (2) v. Level (7) 0.941 (0.797, 1.111) 0.956 (0.816, 1.120) 0.960 (0.822, 1.120)
Level (3) v. Level (7) 0.924 (0.769, 1.112) 0.947 (0.795, 1.129) 0.940 (0.792, 1.115)
Level (4) v. Level (7) 0.997 (0.831, 1.197) 0.995 (0.836, 1.185) 1.008 (0.850, 1.195)
Level (5) v. Level (7) 1.215 (0.859, 1.720) 1.262 (0.909, 1.751) 1.294 (0.941, 1.778)
Level (6) v. Level (7) 1.002 (0.771, 1.302) 1.019 (0.793, 1.308) 1.061 (0.833, 1.351)
Clinical setting at index visit
OPD v. in-patient 0.051 (0.044, 0.058)** 0.059 (0.052, 0.067)** 0.063 (0.056, 0.072)**
ER v. in-patient 0.842 (0.718, 0.987)* 0.813 (0.696, 0.948)* 0.797 (0.683, 0.928)*
Physician type at index visit
Psychiatrist v. non-psychiatrist 5.741 (4.911, 6.711)** 4.975 (4.302, 5.753)** 4.743 (4.117, 5.463)**
Catastrophic card
Yes v. no 1.456 (1.318, 1.609)** 1.531 (1.393, 1.683)** 1.563 (1.425, 1.714)**
Initial diagnosis codes
296.0 v. 296.7 1.575 (1.329, 1.868)** 1.640 (1.399, 1.922)** 1.652 (1.415, 1.928)**
296.1 v. 296.7 1.658 (1.370, 2.007)** 1.632 (1.359, 1.958)** 1.641 (1.373, 1.961)**
296.4 v. 296.7 1.848 (1.594, 2.143)** 1.885 (1.638, 2.169)** 1.911 (1.666, 2.192)**
296.5 v. 296.7 1.012 (0.854, 1.200) 0.998 (0.851, 1.172) 1.023 (0.876, 1.195)
296.6 v. 296.7 1.131 (0.934, 1.368) 1.144 (0.958, 1.367) 1.169 (0.984, 1.389)
Total healthcare costs in the preceding year
(in 1000 NTD)
1.001 (1.000, 1.001)** 1.001 (1.000, 1.001)** 1.001 (1.000, 1.001)**
Note: Other adjusted variables (not shown here) in the Cox regressions included comorbid physical and mental illnesses over the 12-month pre-index period.
OPD, out-patient department; ER, emergency room; CI, confidence interval; NTD, New Taiwan Dollar.
a. Insurance premium was classified into four different levels: Level (1): Under 17 280 NTD; Level (2): Between 17 281 NTD and 36 300 NTD; Level (3): Between 36 301 NTD and 72 800
NTD; Level (4): Above 72 801 NTD.
b. Urbanisation was classified into seven different levels: Level (1): Metropolitan city; Level (2): City; Level (3): Developing city; Level (4): Town; Level (5): Ageing population town; Level (6):
Agricultural town; Level (7): Rural area.
*P<0.05, **P<0.001.
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have been considered as barriers to effective healthcare, this is not
the major cause here because the exemptions of health insurance
premiums and copayments make all health services and treatments
in Taiwan essentially free for those from low-income households.
On the other hand, the presence of other barriers – lack of
knowledge or fear of stigma – may at least partly account for the
poorer outcomes of hospital treatment and excess mortality. For
instance, education levels and certain ethnic minorities have been
reported to be associated with stigma and adherence to treatments
in people with BPD.23,24 Although lifestyle and health-related
behaviours have been considered major determinants of the
population distribution of health and disease, barriers such as
material constraints, and limited opportunities to take up health
promoting messages may further prohibit lower socioeconomic
groups to adopt a healthy lifestyle.25–28 Indeed, we found that those
from low-income households had more physical and mental
comorbidities in the current study cohort. Considering the well-
recognised associations between socioeconomic deprivation and
multimorbidity,29 these participants from low-income households
may suffer from increased morbidities, thus leading to a more
refractory disease course, poorer hospital treatment outcomes,
higher treatment costs and ultimately higher mortality rates. Special
care should be taken to address the unmet needs of de-stigmatisa-
tion and to enhance adherence as well as to reduce health-harming
behaviours for those who are socioeconomically disadvantaged.
Another plausible explanation for the differential outcomes
across socioeconomic groups with BPD may arise from potential
differences in the disease subtypes. For instance, family income
was shown to be associated with self-reported mood symptoms in
bipolar disorder individuals.30 More specifically, a subtype of BPD,
the lithium-responsive form, was reported to be associated with
higher socioeconomic status compared with those continuing to
relapse.31 This subtype was linked to a strong family history32,33
and more likely to present with a non-rapid cycling course with
full remission between episodes.34 In accordance with the afore-
mentioned study showing higher socioeconomic status of people
with lithium-responsive BPD,31 offspring of lithium responder
parents with BPD were also shown to be more socially successful
than those of lithium non-responders.35 Because many of the earlier
studies on socioeconomic status and risk for BPD examined samples
of participants who were mainly lithium-responsive BPD – during
the era when the diagnosis of BPD was used primarily for
individuals with classical presentation, lithium was reported to be
helpful for up to 80% of cases,36 whereas in recent studies using
broad criteria, the benefit of lithium decreased tremendously,
ranging from non-existent37 to only 30%,38 the predominant
findings between higher socioeconomic status and risk of BPD in
earlier literature13,39 may be due, in part, to the over-representation
of lithium-responsive BPD. Future study to further elucidate the
socioeconomic status effects on outcomes in bipolar individuals of
different subtypes is warranted.
In people with BPD, younger age was ever reported to have
negative effects on the odds of remission4 as well as re-hospital
treatment at longitudinal follow-ups.6,7 In agreement with pre-
vious findings, we found that younger age was associated with
higher odds of hospital treatment. We also found that male gender
predicted higher likelihoods of being hospitalised as well as higher
Table 3 Factors predicting total healthcare costs in the second
and third year after index diagnosis
Exp(β)
Second-year costs Third-year costs
First-year healthcare
utilisation patterna
Hospital treatment
v. OPD 4–6
2.267 (2.068, 2.485)** 2.192 (1.998, 2.406)**
OPD ≥7 v. OPD 4–6 1.242 (1.168, 1.32)** 1.177 (1.106, 1.253)**
Age 1.01 (1.008, 1.012)** 1.009 (1.007, 1.011)**
Gender
Male v. female 1.053 (1.001, 1.107)* 1.095 (1.040, 1.153)*
Low-income
household
Yes v. no 1.883 (1.642, 2.160)** 1.480 (1.285, 1.703)**
Insurance premiumb
Level (1) v. Level (4) 1.072 (0.822, 1.398) 0.959 (0.729, 1.262)
Level (2) v. Level (4) 0.936 (0.716, 1.222) 0.878 (0.666, 1.157)
Level (3) v. Level (4) 0.783 (0.594, 1.033) 0.821 (0.617, 1.094)
Urbanisation levelc
Level (1) v. Level (7) 1.125 (1.021, 1.241)* 1.108 (1.003, 1.224)*
Level (2) v. Level (7) 1.143 (1.037, 1.260)* 1.141 (1.033, 1.261)*
Level (3) v. Level (7) 1.053 (0.946, 1.173) 1.083 (0.970, 1.210)
Level (4) v. Level (7) 1.108 (0.994, 1.236) 1.162 (1.039, 1.299)*
Level (5) v. Level (7) 1.082 (0.866, 1.350) 1.363 (1.084, 1.713)*
Level (6) v. Level (7) 1.015 (0.862, 1.195) 1.101 (0.932, 1.301)
Clinical setting at
index visit
OPD v. in-patient 1.107 (1.003, 1.221)* 1.238 (1.120, 1.368)**
ER v. in-patient 1.334 (1.167, 1.526)** 1.331 (1.160, 1.528)**
Physician type at
index visit
Psychiatrist v.
non-psychiatrist
0.979 (0.914, 1.048) 0.936 (0.871, 1.006)
Catastrophic card
Yes v. no 1.534 (1.443, 1.630)** 1.506 (1.415, 1.603)**
Initial diagnosis codes
296.0 v. 296.7 1.041 (0.948, 1.143) 1.021 (0.927, 1.124)
296.1 v. 296.7 1.111 (0.991, 1.245) 1.065 (0.947, 1.198)
296.4 v. 296.7 1.094 (1.004, 1.191)* 1.101 (1.009, 1.201)*
296.5 v. 296.7 1.002 (0.921, 1.090) 0.956 (0.877, 1.042)
296.6 v. 296.7 1.045 (0.951, 1.150) 1.016 (0.921, 1.121)
Total healthcare costs
in the preceding year
(in 1000 NTD)
1.003 (1.003, 1.003)** 1.003 (1.002, 1.003)**
Note: Other adjusted variables (not shown here) in the cost models included comorbid
physical and mental illnesses over the 12-month pre-index period.
OPD, out-patient department; ER, emergency room; CI, confidence interval; NTD,
New Taiwan Dollar.
a. Study participants were grouped by first-year healthcare utilisation pattern for
treatment of BPD: hospital treatment, participants who had been admitted at
least once during the first year; OPD ≥7, participants who had not been
admitted and had ≥7 out-patient visits during the first year; OPD 4–6,
participants who had not been admitted and had 4–6 out-patient visits during
the first year.
b. Insurance premium was classified into four different levels: Level (1): Under 17 280
NTD; Level (2): Between 17 281 NTD and 36 300 NTD; Level (3): Between 36 301
NTD and 72 800 NTD; Level (4): Above 72 801 NTD.
c. Urbanisation was classified into seven different levels: Level (1): Metropolitan city;
Level (2): City; Level (3): Developing city; Level (4): Town; Level (5): Ageing
population town; Level (6): Agricultural town; Level (7): Rural area.
*P<0.05, **P<0.001.
Table 4 Standardised mortality ratios
Participant group
SMRa for death in
2008–2011 (95% CI)
All BPD individuals 2.97 (2.71–3.24)*
Male 3.42 (3.04–3.82)*
Female 2.45 (2.12–2.83)*
BPD individuals from low-income households 5.80 (3.79–8.51)*
Male 5.51 (3.21–8.81)*
Female 6.47 (2.96–12.28)*
Participants without mental illness (sensitivity
analysis)
1.08 (1.04–1.12)*
Male 1.02 (0.98–1.07)
Female 1.18 (1.11–1.24)*
CI, confidence interval.
a. Compared with Taiwan’s general population in 2009–2010.
*P<0.05.
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total healthcare costs over the following years. Indeed, existing
evidence suggested that both young age and male gender
negatively affected adherence to treatment in individuals with
BPD.40 Additionally, we found a considerably higher SMR in
female patients with BPD who were from low-income households.
Although some evidence indicated a stronger association between
low socioeconomic status and high probability of multimorbidity
in women than in men,29 the extent to which the association
between socioeconomic status and excess mortality in females
with BPD could be attributed to this multimorbidity phenomenon
remains to be determined.
Strengths and limitations
The strengths of the current study included whole country
coverage, inclusion of bipolar disorder individuals diagnosed in
all clinical settings, longitudinal follow-up for consecutive 3 years,
examinations of socioeconomic status at both personal and
household levels and provision of the rarely available data on
the relationship between socioeconomic status, outcomes of
hospital treatment and mortality, as well as future healthcare
costs, which could be of great interest to both clinicians and policy
makers. By including only newly diagnosed BPD individuals, the
current study further minimised the bias in the baseline socio-
economic status because of illness-related social decline.
As service use data contained in the NHIRD includes only
health services provided by the NHI system in Taiwan, the
perspective of the current cost analysis was limited. In lack of
exact income data, we performed analyses based on the indivi-
dual’s insurance premium level. Use of proxy definition of death
was another limitation but the sensitivity analysis of SMR in a
control group of people without mental illnesses yielded a
reasonably similar death rate with that of Taiwan’s general
population. In effort to better assure for the validity of the BPD
diagnoses, we only recruited participants who had at least four
out-patient visits under diagnoses of BPD or at least one
admission because of BPD treatment within the first year in this
analysis. With the stringent criterion, we were able to identify a
group of bipolar disorder individuals with more definite clinical
diagnoses but the generalisability to those with a better illness
course or milder form of bipolar spectrum disorders is conse-
quently limited. Given the mean age of 44 years old, the study
participants might not be fresh cases who had never been
diagnosed or treated for BPD. It should be also borne in mind
that sample sizes of certain comparison groups were small, for
instance, only 264 BPD individuals were from low-income
households, which was a limitation.
In conclusion, the current study, with the design of exploratory
nature, suggests that socioeconomic deprivation in people with
BPD may be associated with poorer treatment outcomes, excess
mortalities and higher total healthcare costs based on a large
national database. Special care should be given to those with lower
socioeconomic status to improve participants’ health outcomes
with potential benefits of cost-savings in the following years.
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